Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...

Will these developments be enough to sustain the rally? Let's discuss whether Vertex Pharmaceuticals stock is a buy now. The past year has been transformative for Vertex, marked by the launch of ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other stocks that Jim Cramer discusses. On Thursday, April 3 rd, the host of ...

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (VRTX) (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets close.

At the 2025 Napa Valley Biotech Forum, JPMorgan analyst Jessica Fye walked away with a bullish tone after conversations with Vertex CEO Reshma Kewalramani and Senior Vice President of Investor ...

Vertex and Alnylam are seen as most resilient ... Morningstar reports that with the U.S. importing approximately $200 billion in pharmaceuticals in 2024, a 10% tariff could have cost the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...